EP0357788A1 - Pyridazinone derivatives. - Google Patents

Pyridazinone derivatives.

Info

Publication number
EP0357788A1
EP0357788A1 EP89902288A EP89902288A EP0357788A1 EP 0357788 A1 EP0357788 A1 EP 0357788A1 EP 89902288 A EP89902288 A EP 89902288A EP 89902288 A EP89902288 A EP 89902288A EP 0357788 A1 EP0357788 A1 EP 0357788A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
compound
alkoxy
represents hydrogen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP89902288A
Other languages
German (de)
French (fr)
Other versions
EP0357788B1 (en
Inventor
You Odawara Research Ce Kusase
M Odawara Research Ce Murakata
N Odawara Research C Mochizuki
M Odawara Research Takebayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Soda Co Ltd
Original Assignee
Nippon Soda Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Soda Co Ltd filed Critical Nippon Soda Co Ltd
Priority to AT89902288T priority Critical patent/ATE96786T1/en
Publication of EP0357788A1 publication Critical patent/EP0357788A1/en
Application granted granted Critical
Publication of EP0357788B1 publication Critical patent/EP0357788B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/36—Benzo-cinnolines

Definitions

  • the present invention relates to new pyridazinone derivatives and the processes for the production of such compounds.
  • cardiotonic drugs Several drugs under development are known as cardiotonic drugs.
  • the following compounds are typical examples:
  • the purpose of the present invention is to seek a new substance that has an excellent cardiotonic action and that is safe and free from side effects. It is also to offer the method in which this new substance can be manufactured in a commercially advantageous manner.
  • the present invention relates to a compound having the formula below , and the proces ses for the production of such compound:
  • Y represents C 1- 4 alkylene which may be substituted by C 1-18 alkyl, C 1- 5 alkoxy, C 1- 5 alkylthio C 1- 5 alkyl,
  • each r 1 and r 2 represents hydrogen, C 1-18 alkyl, C 1- 5 alkoxy, C 1-5 alkylthio C 1-5 alkyl, C 1-5 alkoxycarbonyl or benzyl);
  • R 1 represents hydrogen, C 1-5 alkyl which may be substituted by C 1-5 alkoxy, acetyl or C 2-5 alkenyl;
  • R 2 represents hydrogen or methyl; and each R 3 and R 4 represents hydrogen, halogen, hydroxy, C 1-5 alkyl, or C 1-5 alkoxy: and
  • R 5 represents hydrogen or C 1-5 alkyl which may be substituted by hydroxy
  • R 4 and R 5 may form ring by joining each other;
  • the compounds of the present invention exhibit a potent and selective inhibition of the phosphodiesterase III, have an excellent cardiotonic activity, are safe, non-toxic and orally effective, and are useful for the treatment of congestive heart failure.
  • the compounds of the present invention inhibit a platelet aggregation and have an antithrombotic activity.
  • the compounds of the present invention have a bronchodilatory activity and are useful for the treatment of chronic obstructive pulmonary disease such as asthma and bronchitis.
  • the compounds of the present invention are useful for the treatment of various diseases (hypertension, ulcer, diabetes, cancer, etc.) which are associated with the intracellular level of cyclic AMP.
  • R 1 ' is hydrogen, C 1-5 alkyl which may be substituted by C 1-5 alkoxy, or C 2-5 alkenyl.
  • the reaction is carried out in an inert organic solvent, preferably in such a solvent as benzene, toluene, xylene, a lower alcohol or DMF, in the presence of an acid catalyst, preferably such a catalyst as hydrochloric acid, sulfuric acid, acetic acid or paratoluene sulfonic acid, at room temperature or by heating to a temperature above room temperature to 200 °C.
  • the reaction may be performed more efficiently if formed water is removed by such a means as azeotropic dehydration during the reaction.
  • R 1 is acetyl:
  • R" 2 is acetyl, and X is C 1-5 alkoxy.
  • reaction Is carried out in an inert organic solvent, preferably in such a solvent as a lower alcohol or DMF, at room temperature or by heating to a temperature above room temperature to 200 °C. After the reaction is completed, a usual post-treatment gives the intended product.
  • an inert organic solvent preferably in such a solvent as a lower alcohol or DMF
  • the structure of the compounds of this invention has been determined from IR, NMR, MASS spectra, etc.
  • the compounds of this invention are expressed as pyridazinone-3(2H)-one compounds.
  • the pyridazinone part can be a tautomer of pyridazinol, and if R 2 is hydrogen, the cycloacetylamino part be a tautom of enol form or keto form shown below.
  • each raw material having the formula (II), (III) or (IV) can be a simimilar .tautomer.
  • Example 1 4 5-Dihydro-6- ( ( 4- ( 3-oxo-1- cyclopentenyl)amino)phenyl)-3(2H)-pyridazinone (Compound No. 2)
  • the solution was extracted with a mixture of chloroform/2- propanol (3:2) and the combined extracts were dried with anhydrous magnesium sulfate.
  • Test 1 Cardiotonic action: Electrically stimulating isolated guinea pig left atria
  • the hearts were excised from the animals.
  • the left atria were dissected from the hearts and mounted in an organ bath.
  • the bath was filled with 50 ml oxygenated (95% O 2 and 5% CO 2 ) Krebs-Henseleit solution at 30°C of the following composition: NaCl 118 mM; KCl 4.7 mM; CaCl 2 ⁇ 2H 2 O 2.5 mM; MgSO 4 ⁇ 7H 2 O 1.2 mM; KH 2 PO 4 1.2 mM; NaHCO 3 25.0 mM; glucose 10.0 mM.
  • the atria were stimulated by square wave pulses of 3 msec duration and a voltage ranging from 1.2-fold to 1.5-fold of the threshold at a frequency of 6 ⁇ /min with an electric stimulator.
  • test compounds were added cumulatively to the bath and the concentrations causing a 50% increase in contractility
  • the animals were anesthetized with sodium pentobarbital (30 mg/kg, i.v.) and maintained by an intravenous infusion of the anesthetic at a rate of 4 mg/kg per hour.
  • a cuffed endotracheal tube was inserted and an artificial respirator installed.
  • the animals were ventilated with room air in a tidal volume of 20 ml/kg at a rate of 20 brearhs per minute.
  • Cannulae were inserted into the femoral vein for a falling drop of a physiological saline or for an infusion of the anesthetic, and into the femoral artery for measuring arterial blood pressure with a pressure transducer.
  • Heart rate was recorded with a heart rate counter triggered by the R wave of the electrocardiogram (ECG) .
  • ECG electrocardiogram
  • ECG in standard lead II was monitored with a bioelectric amplifier.
  • Left ventricular pressure was measured with a catheter tip pressure transducer inserted via the right carotid artery into the left ventricle.
  • Left ventricular dp/dt max was obtained by an electric differentiator.
  • the compounds were injected through the cannula in the femoral vein at a dose of .0.001-0.3 mg/0.1 ml/kg.
  • the doses producing a 50% increase in LVdp/dt max were calculated from the dose-response curves.
  • Test 3 Inhibition of phosphodiesterase
  • the three active forms of phosphodiesterase (PDE-I, PDE-II, PDE-III) present in the ventricular muscles were discretely eluted from a DEAE-cellulose column (Whatman, DE-52, ⁇ 2.5 ⁇ 20 cm) using a continuous 70-800 mM sodium acetate gradient.
  • the concentrations causing a 50% inhibition of the phosphodiesterase activity were calculated from the concentration-inhibition curves.
  • Test 4 Acute toxicity
  • test compounds The acute toxicity of the test compounds was studied in male mice after oral administration of a single dose. The animals were observed for 7 days and the mortality was determined.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Composé de formule (I) présentant une excellente action cardiotonique. Dans ladite formule, Y représente un alkylène C1-4 pouvant être substitué par un alkylke C1-18, un alcoxy C1-5, un alkyle C1-5 alkylthio C1-5, un alcoxycarbonyle C1-5 ou un benzyle, ou (a) où chaque r1 et r2 représente hydrogène, un alkyle C1-18, un alcoxy C1-5, un alkyle C1-5 alkylthio C1-5, un alcoxycarbonyle C1-5 ou un benzyle; et R1 représente hydrogène, un alkyle C1-5 pouvant être substitué par un alcoxy C1-5, un acétyle ou un alcényle C2-5; R2 représente hydrogène ou un méthyle; chaque R3 et R4 représente hydrogène, un halogène, un hydroxy, un alkyle C1-5 ou un alcoxy C1-5; R5 représente hydrogène ou un alkyle C1-5 pouvant être substitué par un hydroxy; R4 et R5 peuvent former un noyau en s'unissant, et -- représente une liaison simple ou double.Compound of formula (I) having an excellent cardiotonic action. In said formula, Y represents a C1-4 alkylene which can be substituted by a C1-18 alkyl, a C1-5 alkoxy, a C1-5 alkylthio C1-5 alkyl, a C1-5 alkoxycarbonyl or a benzyl, or (a) where each r1 and r2 represents hydrogen, C1-18 alkyl, C1-5 alkoxy, C1-5 alkylthio C1-5 alkyl, C1-5 alkoxycarbonyl or benzyl; and R1 represents hydrogen, C1-5 alkyl which may be substituted by C1-5 alkoxy, acetyl or C2-5 alkenyl; R2 represents hydrogen or methyl; each R3 and R4 represents hydrogen, halogen, hydroxy, C1-5 alkyl or C1-5 alkoxy; R5 represents hydrogen or C1-5 alkyl which may be substituted by hydroxy; R4 and R5 can form a nucleus by uniting, and - represents a single or double bond.

Description

DESCRIPTION
Pyridazinone Derivatives
Technical Field:
The present invention relates to new pyridazinone derivatives and the processes for the production of such compounds.
Background Art :
Several drugs under development are known as cardiotonic drugs. The following compounds are typical examples:
The purpose of the present invention is to seek a new substance that has an excellent cardiotonic action and that is safe and free from side effects. It is also to offer the method in which this new substance can be manufactured in a commercially advantageous manner.
Disclosure of Invention:
The present invention relates to a compound having the formula below , and the proces ses for the production of such compound:
wherein Y represents C 1- 4 alkylene which may be substituted by C1-18 alkyl, C 1- 5 alkoxy, C 1- 5 alkylthio C 1- 5 alkyl,
C 1-5 alkoxycarbonyl or benzyl, or (where each r1 and r2 represents hydrogen, C1-18 alkyl, C 1- 5 alkoxy, C 1-5 alkylthio C 1-5 alkyl, C 1-5 alkoxycarbonyl or benzyl); and
R1 represents hydrogen, C 1-5 alkyl which may be substituted by C 1-5 alkoxy, acetyl or C 2-5 alkenyl; and
R2 represents hydrogen or methyl; and each R3 and R4 represents hydrogen, halogen, hydroxy, C 1-5 alkyl, or C 1-5 alkoxy: and
R5 represents hydrogen or C 1-5 alkyl which may be substituted by hydroxy; and
R4 and R5 may form ring by joining each other; and
= represents single or double bond. Compared to milrinone and CI-914, the compounds of the present invention exhibit a potent and selective inhibition of the phosphodiesterase III, have an excellent cardiotonic activity, are safe, non-toxic and orally effective, and are useful for the treatment of congestive heart failure. In addition, the compounds of the present invention inhibit a platelet aggregation and have an antithrombotic activity. The compounds of the present invention have a bronchodilatory activity and are useful for the treatment of chronic obstructive pulmonary disease such as asthma and bronchitis.
Moreover, the compounds of the present invention are useful for the treatment of various diseases (hypertension, ulcer, diabetes, cancer, etc.) which are associated with the intracellular level of cyclic AMP.
Best Mode for Carrying Out the Invention:
The compounds under the present invention can be manufactured in the methods specified below, (a) when R1 is not acetyl:
wherein R1 ' is hydrogen, C 1-5 alkyl which may be substituted by C 1-5 alkoxy, or C 2-5 alkenyl. The reaction is carried out in an inert organic solvent, preferably in such a solvent as benzene, toluene, xylene, a lower alcohol or DMF, in the presence of an acid catalyst, preferably such a catalyst as hydrochloric acid, sulfuric acid, acetic acid or paratoluene sulfonic acid, at room temperature or by heating to a temperature above room temperature to 200 °C. The reaction may be performed more efficiently if formed water is removed by such a means as azeotropic dehydration during the reaction. (b) when R1 is acetyl:
Wherein R"2 is acetyl, and X is C 1-5 alkoxy.
The reaction Is carried out in an inert organic solvent, preferably in such a solvent as a lower alcohol or DMF, at room temperature or by heating to a temperature above room temperature to 200 °C. After the reaction is completed, a usual post-treatment gives the intended product.
The structure of the compounds of this invention has been determined from IR, NMR, MASS spectra, etc.
The compounds of this invention are expressed as pyridazinone-3(2H)-one compounds. However, the pyridazinone part can be a tautomer of pyridazinol, and if R2 is hydrogen, the cycloacetylamino part be a tautom of enol form or keto form shown below.
In addition, if R5 is a methyl group and = is a single bond in the compound of this invention, an optical isomer is present. This invention includes all these isomers.
Furthermore, each raw material having the formula (II), (III) or (IV) can be a simimilar .tautomer.
The following Examples illustrate the present invention. Example 1 4 , 5-Dihydro-6- ( ( 4- ( 3-oxo-1- cyclopentenyl)amino)phenyl)-3(2H)-pyridazinone (Compound No. 2)
430 mg of 4,5-dihydro-6-(4-aminophenyl)-3(2H)-pyridazinone and 220 mg of cyclopentane-1,3-dione were suspended in 4 ml of ethanol, to which 2 ml of acetic acid was added. The resulting mixture was heated to reflux for 2 hours. After cooled, deposited crude crystal was collected by filtrating, and purified by silica gel column chromatography (eluting solvent: chloroform: methanol = 10:1). 520 mg of the title compound was obtained, m.p.: >360°C. NMR (solvent: DMSO-d6) : δ 1.80 - 2.80 (m, 8H), 5.13 (S, 1H), 7.10 (dd, 4H), 9.33 (S, 1H), 10.50 (S, 1H).
Example 2 4,5-Dihydro-6-(4-((2-methyl-3-oxo-1- cyclopentenyl)-amino)phenyl)-3(2H)-phridazinone (Compound. No . 4) y
3.4 g of 4.5-dihydro-6-(4-aminophenyl)-3(2H)-pyridazinone and 2.0 g of 2-methylcyclopentane-1,3-dione were suspended in 30 ml of toluene, to which a catalytic amount of p-toluene sulfonate-hydrate was add while the resulting suspension was heated to reflux with stirring for 8 hours, with removal of water as an azcotropic mexture. After cooled, deposited crude crystal was collected by filtrating, and purified by silica gel column chromatography (eluting solvent: chloroform: methanol = 10:1). 4.7 g of the title compound was obtained. m.p. 284- 285 ºC
Example 3 : 3,5-Dihydro-6-(4-((2-acetyl-5,5-dimethyl-3-oxo-1- cyclohexenyl)amino)phenyl)-3(2H) pyridazinone (Compound No. 6)
230 mg of 2-acetyl-5,5-dimethyl-3-methoxy-2-cyclohexen-1- one and 284 mg of 4,5-dihydro-6-(4-aminophenyl)-3(2H)- pyridazinone was suspended in 2 ml of ethanol, and the resulting mixture was heated to reflux for an hour. After cooled, crude crystal was collected by filtrating, and purified by silica gel column chromatography (eluting solvent: chloroform: methanol = 30:1). 390 mg of the title compound was obtained, m.p. 212.0-213.5°C. Example 4 : 4 , 5-Dihydro-β- ( 4- ( ( 3-oxo-1- cyclopentenyl)amino)phenyl)-5-methyl-3(2H)- pyridazinone (Compound No. 14)
0.51 g of 4,5-dihydro-6-(4-aminophenyl)-5-methyl-3(2H)- pyridazinone and 0.25 g of cyclopentane-1,3-dione were suspended in a mixture of 5 ml of ethanol and 5 ml of acetic acid and the resulting suspension was refluxed for 7 hours.
After cooled, deposited crude crystal was collected by filtrating and recrystallized from DMF-heptane-CHCl3 to give
0.24 g of the title compound, m.p. >300°C. NMR (solvent DMSO- d6-CDCl3) δ 1.20 (d, 3H), 2.32-3.32 (m, 7H), 5 - 60 (S, 1H), 7.56 (dd, 4H), 9.82 (S, 1H), 10.80 (S, 1H).
Example 5 : 4,5-Dihydro-6-(4-((2-methyl-3-oxo-1- cyclopentenyl)amino)phenyl)-5-methyl-3(2H)- pyridazinone (Compound No. 15)
A mixture of 0.51 g of 4,5-dihydro-6-(4-aminophenyl)-5- methyl-3(2H) pyridazinone and 0.28 g of 2-methyl-cyclopentane- 1,3-dione in 5 ml of ethanol and 5 ml of acetic acid was refluxed over night. After cooling, the solution was evaporated in vacuo. The residue was purified by silica gel column chromatography (eluting solvent: chloroform: methanol = 20:1) and recrystallized from methanol to give 0.32 g of the title compound, m.p.285-286°C.
Reference Example 1 : 7-Acetamido-3-cyanomethylchroman-4-one
A mixture of 37% aqueous formaldehyde (1 ml) and dimethylamine hydrochloride (l.lg) were stirred at room temperature for one hour.
After an addition of acetic anhydride (6 ml) the mixture was gradually heated until a one-phase system resulted.
To the solution 7-acetamidochroman-4-one (1.5 g, 7.3 m mole) was added, and the solution was heated ( 90-100ºC) for one hour.
The solvent was removed under reduced pressure, acetone (20 ml) was added, and the solution was heated at reflux for 15 minutes. A residue obtained by evaporation of solvent under reduced pressure was dissolved in 1N aqueous NaOH (50 ml).
The solution was extracted with a mixture of chloroform/2- propanol (3:2) and the combined extracts were dried with anhydrous magnesium sulfate.
After remove of magnesium sulfate the solvent was evaporated to provide an oil.
After an addition of methyl iodide (2.8 g, 20 m mole) to the oil in acetone (50 ml), the solution was heated at reflux for one hour. After cooling the resulting solid was collected to provide the quaternary salt (1.78 g, yield 60.4%).
To a suspension of quaternary salt (510 mg, 1.26 m mole) in a mixture of methanol/water (1:1, 10 ml), potassium cyanide (100 ml, 1.54 m mole) in water (2 ml) was added.
The mixture was stirred at room temperature for eight hours. Then, the resulting solid was collected to provide 7-acetamido-3-cyanomethylchroman-4-one (200 mg. Yied 65.1%). (NMR (CD3OD), δ: 2.13 (3H, S), 2.70-3.00 (2H, m), 4.10-4.83 (3H, m), 7.05 (1H, dd), 7.43 (1H,d), 7.73 (1H, d))
Reference Example 2 : 8-Amino-3,4,4a,5-tetrahydro-2H-(1) benzopyrano (4,3-e)pyridazin-3-one
A suspension of 7-acetamido-3-cyanomethylchroman-4-one (200 mg, 0.82 m mole) in 6N aqueous HCl (8 ml) was heated at reflux for one hour. After cooling 6N aqueous NaOH was added until a solution was adjusted to pH 5, and 100% hydrazine hydrate (100 mg, 2 m mole) was added.
Then the solution was heated at reflux for 4 hours. After cooling the product was collected to provide 8-amino-3,4,4a,5-tetrahydro-2H-(l)benzopyrano(4,3-c)pyridazin-3-one (130 mg, yield 73-1%), m.p. 232-235 °C (dec.)
Example 6 : 8-(3-oxo-1-cyclopentenylamino)-3,4,4a,5- tetrahydro-2H-(1)benzopyrano(4,3-c)-pyridazinon-3- one (Compound No. 24)
To a suspension of 8-amino-3,4,4a,5-tetrahydro-2H-(1)benzopyrano(4,3-c)pyridazin-3-one (130 mg, 0.6 m mol) in a mixture of ethanol/acetic acid (1:1, 2ml), 1.3-cyclopentanedlone (120 mg, 1.2 m mole) was added, and the suspension was heated at reflux for 4 hours.
A residue obtained by evaporation of solvent was chromatographed on silica gel (eluting solvent: chloroform: metanol = 50:1) to provide the tile compound (170 mg, yield 95%). m.p. 327ºC (dec.)
Inclusive the above, each compound within the scope of this invention which can be prepared in analogous method(s) is tabulated in Table 1. Industrial Applicability:
The pharmacological effects in the compounds of the present invention is described by the following tests.
Test 1 : Cardiotonic action: Electrically stimulating isolated guinea pig left atria
Male Hartley guinea pigs weighing 350-500 g were used.
The hearts were excised from the animals. The left atria were dissected from the hearts and mounted in an organ bath.
The bath was filled with 50 ml oxygenated (95% O2 and 5% CO2) Krebs-Henseleit solution at 30°C of the following composition: NaCl 118 mM; KCl 4.7 mM; CaCl2·2H2O 2.5 mM; MgSO4·7H2O 1.2 mM; KH2PO4 1.2 mM; NaHCO3 25.0 mM; glucose 10.0 mM.
The atria were stimulated by square wave pulses of 3 msec duration and a voltage ranging from 1.2-fold to 1.5-fold of the threshold at a frequency of 6θ/min with an electric stimulator.
Resting tension was adjusted to 0.5 g and contraction was recorded on the Polygraph Systems with a force-displacement transducer.
All preparations were allowed to equilibrate with the bath medium for 90 to 120 min.
The test compounds were added cumulatively to the bath and the concentrations causing a 50% increase in contractility
(EC50) were calculated from the concentration-response curves.
The results are shown in Table 2.
Test 2 : Cardiotonic action: Anesthetized dogs
Adult mongrel dogs of either sex weighing 8 to 15 kg were used.
The animals were anesthetized with sodium pentobarbital (30 mg/kg, i.v.) and maintained by an intravenous infusion of the anesthetic at a rate of 4 mg/kg per hour.
A cuffed endotracheal tube was inserted and an artificial respirator installed. The animals were ventilated with room air in a tidal volume of 20 ml/kg at a rate of 20 brearhs per minute.
Cannulae were inserted into the femoral vein for a falling drop of a physiological saline or for an infusion of the anesthetic, and into the femoral artery for measuring arterial blood pressure with a pressure transducer. Heart rate was recorded with a heart rate counter triggered by the R wave of the electrocardiogram (ECG) .
ECG in standard lead II was monitored with a bioelectric amplifier.
Left ventricular pressure was measured with a catheter tip pressure transducer inserted via the right carotid artery into the left ventricle. Left ventricular dp/dtmax was obtained by an electric differentiator.
The compounds were injected through the cannula in the femoral vein at a dose of .0.001-0.3 mg/0.1 ml/kg.
The doses producing a 50% increase in LVdp/dtmax (ED50) were calculated from the dose-response curves.
The results are shown in Table 3.
Test 3 : Inhibition of phosphodiesterase
The preparation of different forms of cyclic nucleotide phosphodiesterase from guinea big left ventricular muscles was done by following the procedure of Weishaar, et al. (R. Weishaar, et al., Biochemical Pharmacology, 35., 787-800, 1986) with the minor modified method of Thompson, et al. (W.J. Thompson, et al., Advances in Cyclic Nucleotide Research, 10, 69-92, 1979). Briefly, the three active forms of phosphodiesterase (PDE-I, PDE-II, PDE-III) present in the ventricular muscles were discretely eluted from a DEAE-cellulose column (Whatman, DE-52, Փ 2.5 × 20 cm) using a continuous 70-800 mM sodium acetate gradient.
The phosphodiesterase activity was assayed by minor modifications of the method described by Furutani et al. (Y.
Furutani, et al., Journal of Antibiotics, 28 , 558-560, 1975). Briefly, 1 μM 3Η -cAMP was hydrolyzed by the phosphodiesterase and the unhydrolyzed 3H -cAMP which was separated from the formed 5'-AMP by a dry alumina (Merck, activity 1, neutral) was counted by a liquid scintillation counter.
The concentrations causing a 50% inhibition of the phosphodiesterase activity (IC50) were calculated from the concentration-inhibition curves.
The results are shown in Table 4.
Test 4 : Acute toxicity
The acute toxicity of the test compounds was studied in male mice after oral administration of a single dose. The animals were observed for 7 days and the mortality was determined.
The results are shown in table 5.

Claims

C L A I M S
1. A compound having the formula below and its complex is which pharmaceutical allowable :
wherein Y represents C 1-4 alkylene which may be substituted by C1-18 alkyl, C1-5 alkoxy, C1-5 alkylthio C1-5 alkyl, C1-5
alkoxycarbonyl or benzyl , or (where each r 1 and r2 represents hydrogen , C1-18 alkyl , C1-5 alkoxy , C1-5 alkylthio C1-5 alkyl, C1-5 alkoxycarbonyl or benzyl); and
R1 represents hydrogen, C1-5 alkyl which may be substituted by C1-5 alkoxy, acetyl or C2-5 alkenyl; and
R2 represents hydrogen or methyl; and each R3 and R4 represents hydrogen, halogen, hydroxy, C1-5 alkyl , or C1-5 alkoxy ; and
R5 represents hydrogen or C1-5 alkyl which may be sustituted by hydroxy; and
R4 and R5 may form ring by joining each other; and == represents single or doble bond. A process for the production of a compound having the formula
which comprises reacting a compound having the formula
with a compound having the formula
wherein R'1 represents hydrogen, C1-5 alkyl which may be substituted by C1-5 alkoxy, or C2-5 alkenyl; and Y, R2, R3 , R4 , R5 and
== are as defined above.
3. A process for the production of a compound having the formula
which comprises reacting a compound having the formula
with a compound having the formula
wherein R1" represents acetyl; and
X represents C1-5 alkoxy; and
R2, R3, R4, R5 and == are as defined above.
EP89902288A 1988-02-13 1989-02-09 Pyridazinone derivatives Expired - Lifetime EP0357788B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT89902288T ATE96786T1 (en) 1988-02-13 1989-02-09 PYRIDAZINONE DERIVATIVES.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP3161888 1988-02-13
JP31618/88 1988-02-13
JP75910/88 1988-03-31
JP7591088 1988-03-31

Publications (2)

Publication Number Publication Date
EP0357788A1 true EP0357788A1 (en) 1990-03-14
EP0357788B1 EP0357788B1 (en) 1993-11-03

Family

ID=26370117

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89902288A Expired - Lifetime EP0357788B1 (en) 1988-02-13 1989-02-09 Pyridazinone derivatives

Country Status (11)

Country Link
US (1) US5110925A (en)
EP (1) EP0357788B1 (en)
JP (1) JP2717687B2 (en)
KR (1) KR910005233B1 (en)
CA (1) CA1320957C (en)
DE (1) DE68910447T2 (en)
DK (1) DK170096B1 (en)
ES (1) ES2012646A6 (en)
FI (1) FI95570C (en)
NO (1) NO176275C (en)
WO (1) WO1989007594A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5895137A (en) * 1994-06-14 1999-04-20 Noritsu Koki Co., Ltd. Automatic photographic developing apparatus for photosensitive materials
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2012118972A2 (en) 2011-03-01 2012-09-07 Synegy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8903130D0 (en) * 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
JP2806192B2 (en) * 1992-11-02 1998-09-30 日本曹達株式会社 Platelet aggregation inhibitor
WO1996015117A1 (en) * 1994-11-11 1996-05-23 Nippon Soda Co., Ltd. Optically active compound
EP0961616A4 (en) * 1996-09-13 2000-11-22 Trustees Of Board Of Non-hormonal method of contraception
AU6005999A (en) * 1998-10-09 2000-05-01 Nihon Nohyaku Co., Ltd. Pyridazinone derivatives
US9884806B2 (en) 2013-08-30 2018-02-06 Icahn School Of Medicine At Mount Sinai Cyclic vinylogous amides as bromodomain inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4019575A (en) * 1975-12-22 1977-04-26 Chevron Research Company System for recovering viscous petroleum from thick tar sand
JPS5746966A (en) * 1980-09-03 1982-03-17 Mitsui Toatsu Chem Inc Pyridazinone derivative and its production
US4665174A (en) * 1981-05-12 1987-05-12 Sumitomo Chemical Company, Limited Production of cyclopentenone derivatives
JPS58113180A (en) * 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc Pyridazinone derivative
DE3302442A1 (en) * 1983-01-26 1984-07-26 Basf Ag, 6700 Ludwigshafen NEW PYRIDAZINONE, METHOD FOR THE PRODUCTION THEREOF, THERAPEUTICAL AGENTS CONTAINING THESE COMPOUNDS AND THE USE THEREOF
US4602019A (en) * 1983-04-22 1986-07-22 Warner-Lambert Company Indeno[1,2-c]pyridazin-3-one derivatives useful as cardiotonic and antihypertensive agents
US4666902A (en) * 1983-06-20 1987-05-19 Cassella Aktiengesellschaft Tetrahydropyridazinone derivatives, processes for their preparation and their use
GB2164643B (en) * 1984-07-27 1988-11-02 Boehringer Biochemia Srl Tricyclic dihydropyridazinones and pharmaceutical compositions containing them
JPH06763B2 (en) * 1984-08-28 1994-01-05 吉富製薬株式会社 Benzo [h] cinnoline derivative
US4816454A (en) * 1984-09-21 1989-03-28 Cassella Aktiengesellschaft 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use
US4681621A (en) * 1984-12-20 1987-07-21 Stauffer Chemical Company Herbicidal 2-(2-substituted benzoyl)-1,3-cyclopentanediones
DE3505609A1 (en) * 1985-02-19 1986-08-21 Merck Patent Gmbh, 6100 Darmstadt BENZIMIDAZOLYL PYRIDAZINONE
GB2177689B (en) * 1985-07-09 1989-07-19 Boehringer Biochemia Srl Tricyclic dihydropyridazinones and pharmaceutical compositions containing them
JPH0633277B2 (en) * 1986-01-10 1994-05-02 吉富製薬株式会社 Benzothiopyrano [4,3-C] pyridazine compound
US4775411A (en) * 1986-06-09 1988-10-04 Stauffer Chemica Company Certain substituted 3-amino-2-benzoylcyclohex-2-enones
EP0281045B1 (en) * 1987-03-02 1991-12-27 Yoshitomi Pharmaceutical Industries, Ltd. Benzothiepino (5,4-c) pyridazine compounds and their pharmaceutical uses
DE3804490A1 (en) * 1988-02-12 1989-08-24 Heumann Pharma Gmbh & Co SUBSTITUTED 6-PHENYLDIHYDRO-3 (2H) -PYRIDAZINONE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
JPH0216991A (en) * 1988-07-04 1990-01-19 Mitsui Toatsu Chem Inc Production of l-tryptophan

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8907594A1 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5895137A (en) * 1994-06-14 1999-04-20 Noritsu Koki Co., Ltd. Automatic photographic developing apparatus for photosensitive materials
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2923706A1 (en) 2009-12-03 2015-09-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2012118972A2 (en) 2011-03-01 2012-09-07 Synegy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EP4309673A2 (en) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
EP3708179A1 (en) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP3718557A2 (en) 2013-02-25 2020-10-07 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP4424697A2 (en) 2013-06-05 2024-09-04 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP3492106A1 (en) 2013-08-09 2019-06-05 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP3884935A1 (en) 2013-08-09 2021-09-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Also Published As

Publication number Publication date
NO176275C (en) 1995-03-08
JPH0256468A (en) 1990-02-26
KR900700462A (en) 1990-08-13
EP0357788B1 (en) 1993-11-03
DK502389A (en) 1989-11-20
FI95570C (en) 1996-02-26
DE68910447D1 (en) 1993-12-09
FI894844A0 (en) 1989-10-12
DE68910447T2 (en) 1994-03-17
DK502389D0 (en) 1989-10-10
FI95570B (en) 1995-11-15
KR910005233B1 (en) 1991-07-24
CA1320957C (en) 1993-08-03
NO894088L (en) 1989-10-12
ES2012646A6 (en) 1990-04-01
NO176275B (en) 1994-11-28
DK170096B1 (en) 1995-05-22
US5110925A (en) 1992-05-05
JP2717687B2 (en) 1998-02-18
NO894088D0 (en) 1989-10-12
WO1989007594A1 (en) 1989-08-24

Similar Documents

Publication Publication Date Title
EP0357788B1 (en) Pyridazinone derivatives
CA1139761A (en) Tetrazolylalkoxycarbostyril derivatives and process for producing the same
JP4417622B2 (en) Thieno [2,3-C] isoquinoline for use as an inhibitor of PARP
US4666908A (en) 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US4404203A (en) Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
EP0199127B1 (en) 5-(6-imidazo[1,2-a]pyridyl) pyridine derivative
US4663326A (en) Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
US4613603A (en) Compounds with a nitrogen-containing heterocyclic nucleus, and drugs in which they are present
JPH04217977A (en) Novel benzoxazine and benzothiazine derivative and preparation thereof
FI93013B (en) A process for the preparation of therapeutically useful pyridopyridazinone derivatives
JP3083544B2 (en) Drugs to prevent or treat heart disease
US4940708A (en) 4-arylsulfonyl-3,4-dihydro-2(1H)-quinoxalinone-1-alkanoic acids, esters, and salts
SU1342416A3 (en) Method of producing pyridazinone derivatives or water-soluble salts thereof with pharmaceutically acceptable acid
JPS60174781A (en) Cardiac stimulant and antihypertensive oxadiazinone compound
US4430342A (en) N-Acyl-3-[4-(benzoylalkyl)piperazin-1-yl]-sydnonimine compound, process for prodction thereof, and use thereof
US4808618A (en) Substituted 1,3-dialkylpyrido[4,3-d]pyrimidine-2,4-diones
US4904667A (en) 1H-1,2,4-thiadiazolo(3,4-b)quinazolin-5-one-2,2-dioxides, and a method for increasing the cardiac output of a mammal with them
CZ174397A3 (en) Use of xanthine derivatives for preparing a medicament for treating and prophylaxis of shock diseases, novel xanthine derivatives and process of their preparation
HU196069B (en) Process for production of 8-/dihydropiridil-carbamoiloxi-methil/-ergolines and medical compounds containing these compositions
US4372956A (en) 5, 10-Dihydroimidazo[2,1-b]quinazolines and pharmaceutical compositions containing them
AU621087B2 (en) Pyridazinone derivatives
JPH0662608B2 (en) Carbostyril derivative
US4732906A (en) Dioxolobenzizoxazole derivatives
EP0252986A1 (en) Hydrazone derivatives
JPS62158274A (en) Substituted 1,3-dithiethane derivative

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19891002

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19920701

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19931103

Ref country code: AT

Effective date: 19931103

REF Corresponds to:

Ref document number: 96786

Country of ref document: AT

Date of ref document: 19931115

Kind code of ref document: T

ITF It: translation for a ep patent filed
REF Corresponds to:

Ref document number: 68910447

Country of ref document: DE

Date of ref document: 19931209

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19940228

Ref country code: BE

Effective date: 19940228

BERE Be: lapsed

Owner name: NIPPON SODA CO. LTD

Effective date: 19940228

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20000114

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20000117

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20000122

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20000124

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20000125

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010228

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010901

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20010209

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20011031

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20010901

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20011201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050209